GlaxoSmithKline hits ‘go’ on Adaptimmune’s SPEAR T-cell program – FierceBiotech
FierceBiotech |
GlaxoSmithKline hits 'go' on Adaptimmune's SPEAR T–cell program
FierceBiotech As CAR-T and T–cell therapies continue to make headlines, GlaxoSmithKline has taken up the option to work on Adaptimmune's T–cell therapy. GSK has been shaking up its R&D following the arrival of new CEO Emma Walmsley, including potentially … |
